Overview

• BioCardia Q3 net loss decreases to $1.5 mln from $1.7 mln last year

• Company closed $6 mln financing to support CardiAMP cell therapy initiatives

• Research and development expenses rise due to CardiAMP HF trial activities

Result Drivers

• FINANCING SUPPORT - $6 mln financing supports CardiAMP cell therapy approvability discussions and trials, per CEO Peter Altman

• R&D EXPENSES - Increased R&D expenses driven by CardiAMP HF trial activities

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for BioCardia Inc is $15.50, about 91.4% above its November 11 closing price of $1.33

Press Release: ID:nGNX7yRdQC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)